Menu
Menu
Genomics is changing how we understand cancer
The next chapter is about turning insight into action.
Precision oncology is entering a new era.
As next-generation sequencing, liquid biopsy and advanced genomic technologies continue to evolve, the opportunity is no longer simply to generate more data — but to translate increasingly complex genomic information into clinically meaningful insights.
Insights that can help us:
Join SOPHiA GENETICS for an evening of expert discussion exploring the next chapter in precision oncology — where genomic data, clinical expertise and innovation converge to bring precision medicine closer to the patient.
DR. KOJO S. ELENITOBA-JOHNSON, MD
Chair, Department of Pathology and Laboratory Medicine
Memorial Sloan Kettering Cancer Center
Dr. Kojo S. Elenitoba-Johnson is a physician-scientist specialising in hematopathology and molecular genetic pathology, with more than three decades of experience in pathology and molecular pathology.
His work focuses on genomic and proteomic alterations in lymphoma and their diagnostic and therapeutic applications, including the use of advanced genomic approaches such as next-generation sequencing in hematologic malignancies.
DR. OMShree
Scientific Officer, Molecular Diagnostics & Translational Medicine
Tata Memorial Centre
Dr. Omshree brings a clinical and translational perspective from Tata Memorial Centre, one of India's leading institutions in cancer care, research and education.
Her work contributes to the evolving role of molecular diagnostics and genomic medicine in cancer, and how advances in genomics can translate into meaningful clinical practice and patient care.
DR. SRIDHAR SIVASUBBU
Chief Diagnostics & Research Officer & Lab Director
Karkinos Healthcare
Dr. Sridhar Sivasubbu brings extensive expertise across genomics, molecular diagnostics and precision medicine, with a strong focus on translating genomic science into healthcare.
At Karkinos Healthcare, his work sits at the intersection of diagnostics, research and cancer genomics. He has also been involved in initiatives such as the Bharat Cancer Genome Atlas, supporting the development of genomic resources to advance cancer research and more personalised approaches to cancer care in India.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
